Articles with public access mandates - Patrick FlynnLearn more
Not available anywhere: 5
Introduction to the special issue on organizational dynamics within substance abuse treatment: A complex human activity system
PM Flynn, DK Knight, MD Godley, HK Knudsen
Journal of substance abuse treatment 42 (2), 109-115, 2012
Mandates: US National Institutes of Health
Costs of care for people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders
CJ Conover, M Weaver, A Ang, P Arno, PM Flynn, SL Ettner, ...
AIDS care 21 (12), 1547-1559, 2009
Mandates: US National Institutes of Health
The role of physical and psychological health problems in the drug use treatment process
GW Joe, WEK Lehman, GA Rowan, K Knight, PM Flynn
Journal of substance abuse treatment 102, 23-32, 2019
Mandates: US National Institutes of Health
NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study.
KA Jaeckle, D Schiff, SK Anderson, E Galanis, PJ Stella, PJ Flynn, ...
Journal of Clinical Oncology 29 (15_suppl), 2033-2033, 2011
Mandates: US National Institutes of Health
Does L-arginine/Korean ginseng/gingko biloba/damiana-based supplement improve the sexual function and quality of life of female cancer survivors: A randomized trial.
K Greven, LD Case, LR Nycum, PJ Zekan, DD Hurd, EP Balcueva, ...
Journal of Clinical Oncology 29 (15_suppl), 9016-9016, 2011
Mandates: US National Institutes of Health
Available somewhere: 106
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial
PJ Loehrer Sr, Y Feng, H Cardenes, L Wagner, JM Brell, D Cella, P Flynn, ...
Journal of Clinical Oncology 29 (31), 4105-4112, 2011
Mandates: US National Institutes of Health
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group–directed intergroup trial …
PA Philip, J Benedetti, CL Corless, R Wong, EM O'Reilly, PJ Flynn, ...
Journal of clinical oncology 28 (22), 3605-3610, 2010
Mandates: US National Institutes of Health
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
Mandates: UK Medical Research Council, National Institute for Health Research, UK
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus …
EH Romond, JH Jeong, P Rastogi, SM Swain, CE Geyer Jr, MS Ewer, ...
Journal of Clinical Oncology 30 (31), 3792-3799, 2012
Mandates: US National Institutes of Health
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
KC Bible, VJ Suman, JR Molina, RC Smallridge, WJ Maples, ME Menefee, ...
The lancet oncology 11 (10), 962-972, 2010
Mandates: US National Institutes of Health
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial
RD Carvajal, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, ...
Jama 311 (23), 2397-2405, 2014
Mandates: US National Institutes of Health
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind …
RS Herbst, R Ansari, F Bustin, P Flynn, L Hart, GA Otterson, G Vlahovic, ...
The Lancet 377 (9780), 1846-1854, 2011
Mandates: US National Institutes of Health
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study
E Galanis, KA Jaeckle, MJ Maurer, JM Reid, MM Ames, JS Hardwick, ...
Journal of clinical oncology 27 (12), 2052-2058, 2009
Mandates: US National Institutes of Health
Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients
JL Ryan, CE Heckler, JA Roscoe, SR Dakhil, J Kirshner, PJ Flynn, ...
Supportive care in cancer 20, 1479-1489, 2012
Mandates: US National Institutes of Health
Anthracyclines in early breast cancer: The abc trials—usor 06-090, nsabp b-46-i/usor 07132, and nsabp b-49 (nrg oncology)
JL Blum, PJ Flynn, G Yothers, L Asmar, CE Geyer Jr, SA Jacobs, ...
Journal of clinical oncology 35 (23), 2647-2655, 2017
Mandates: US National Institutes of Health, Susan G. Komen
NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and …
L Fehrenbacher, RS Cecchini, CE Geyer Jr, P Rastogi, JP Costantino, ...
Journal of Clinical Oncology 38 (5), 444-453, 2020
Mandates: US National Institutes of Health
Efficacy of lamotrigine in the management of chemotherapy‐induced peripheral neuropathy: A phase 3 randomized, double‐blind, placebo‐controlled trial, N01C3
RD Rao, PJ Flynn, JA Sloan, GY Wong, P Novotny, DB Johnson, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2008
Mandates: US National Institutes of Health
Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group
SM Ansell, DJ Inwards, KM Rowland Jr, PJ Flynn, RF Morton, DF Moore Jr, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2008
Mandates: US National Institutes of Health
Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions
PD Friedmann, R Hoskinson Jr, M Gordon, R Schwartz, T Kinlock, ...
Substance Abuse 33 (1), 9-18, 2012
Mandates: US National Institutes of Health
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ...
Annals of oncology 33 (12), 1250-1268, 2022
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Publication and funding information is determined automatically by a computer program